BXP (BXP) Bank of America 2024 Global Real Estate Conference summary

Leasing and market dynamics

• Leasing activity accelerated, with 1.3 million sq ft signed in Q2 and 1.8 million sq ft in active Q3 negotiations, potentially surpassing 4 million sq ft for 2024, a significant increase over 2023.

• Most leasing momentum is in Boston, New York, and Northern Virginia, driven by private equity, legal, and FIRE tenants; West Coast markets remain challenging, except for some R&D activity in Silicon Valley.

• Occupancy gains are expected mainly from filling vacant or expiring spaces, with about 700,000 sq ft of current negotiations tied to vacant space.

• Submarket performance varies widely: Back Bay in Boston and Park Avenue in Manhattan are landlord-favorable, while other areas face high availability and slower absorption.

• Life science leasing remains subdued due to funding shifts, excess sublet space, and cautious capital deployment; no new developments planned until demand clarity improves.

Capital strategy and financial outlook

• Floating rate debt exposure is 10–15% ($1.8B); short-term rate declines could lower interest costs, while long-term refinancing needs are minimal for the next year.

• Recent 10-year refinancing at 5.8% secured, with no major long-term maturities due soon; stock price has risen, reflecting improved leasing and rate outlook.

• Commercial paper market and private equity partners are being leveraged for capital flexibility; up to $200M in land sales targeted to raise additional funds.

• Conservative approach to acquisitions, focusing on select opportunities with strong returns and third-party capital, while monitoring market for distressed or capital-starved assets.

• No regrets on prior market entries, with belief in long-term value of LA and life science assets despite timing challenges.

Development and investment plans

• 343 Madison project in Manhattan progressing, with construction start possible in late 2025 and targeted delivery for late 2028–2029; aiming for 8% cash-on-cash return and significant pre-leasing.

• No new life science developments planned until market demand recovers; existing pipeline in Cambridge is fully pre-leased.

• Selective investment in non-office rescue capital and suburban multifamily projects, often with institutional partners to enhance returns.

• Land monetization and entitlements being pursued for near-term and long-term capital generation.